These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 15853558

  • 1. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C, Yang C, O'Reardon J, Ballas P, Baldassano C.
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [Abstract] [Full Text] [Related]

  • 2. Focus on ziprasidone.
    Green B.
    Curr Med Res Opin; 2001 Mar; 17(2):146-50. PubMed ID: 11759185
    [Abstract] [Full Text] [Related]

  • 3. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone.
    Rossi A, Cañas F, Fagiolini A, Larmo I, Levy P, Montes JM, Papageorgiou G, Sturlason R, Zink M, Correll CU.
    Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094
    [Abstract] [Full Text] [Related]

  • 4. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM, Shayegan DK.
    J Clin Psychiatry; 2003 Jan; 64 Suppl 19():6-12. PubMed ID: 14728084
    [Abstract] [Full Text] [Related]

  • 5. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
    Kane JM.
    J Clin Psychiatry; 2003 Jan; 64 Suppl 19():3-5. PubMed ID: 14728083
    [No Abstract] [Full Text] [Related]

  • 6. Strategies for successful clinical management of schizophrenia with ziprasidone.
    Fagiolini A, Cañas F, Gallhofer B, Larmo I, Levy P, Montes JM, Papageorgiou G, Zink M, Rossi A.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2199-220. PubMed ID: 20658947
    [Abstract] [Full Text] [Related]

  • 7. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG.
    J Clin Psychiatry; 2003 Sep; 64 Suppl 19():40-9. PubMed ID: 14728089
    [Abstract] [Full Text] [Related]

  • 8. Ziprasidone (Geodon) for schizophrenia.
    Med Lett Drugs Ther; 2001 Jun 11; 43(1106):51-2. PubMed ID: 11402259
    [No Abstract] [Full Text] [Related]

  • 9. [Exercising caution in choice of psychotropic drugs. Avoid drug-induced weight gain].
    MMW Fortschr Med; 2002 May 06; Suppl 2():89. PubMed ID: 12070872
    [No Abstract] [Full Text] [Related]

  • 10. Maintaining symptom control: review of ziprasidone long-term efficacy data.
    Schooler NR.
    J Clin Psychiatry; 2003 May 06; 64 Suppl 19():26-32. PubMed ID: 14728087
    [Abstract] [Full Text] [Related]

  • 11. Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study.
    Montejo AL, Rico-Villademoros F, Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
    J Clin Psychopharmacol; 2008 Oct 06; 28(5):568-70. PubMed ID: 18794656
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y, Gibel A, Yorkov V, Ritsner MS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1401-9. PubMed ID: 17669574
    [Abstract] [Full Text] [Related]

  • 13. Ziprasidone-induced oculogyric crisis.
    Ramos AE, Shytle RD, Silver AA, Sanberg PR.
    J Am Acad Child Adolesc Psychiatry; 2003 Sep 01; 42(9):1013-4. PubMed ID: 12964566
    [No Abstract] [Full Text] [Related]

  • 14. Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.
    Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Abi-Dargham A, Laruelle M.
    J Psychopharmacol; 2011 Jun 01; 25(6):734-43. PubMed ID: 21109614
    [Abstract] [Full Text] [Related]

  • 15. Brief report on Ziprasidone.
    Firoz AH, Rahman AH, Chowdhury WA, Mamun AA.
    Mymensingh Med J; 2002 Jul 01; 11(2):129-32. PubMed ID: 12395687
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
    Ritsner MS, Yorkov V, Ratner Y, Soifer P, Gibel A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1470-7. PubMed ID: 17669573
    [Abstract] [Full Text] [Related]

  • 17. Drug safety evaluation of ziprasidone.
    Citrome L.
    Expert Opin Drug Saf; 2011 May 01; 10(3):437-48. PubMed ID: 21332416
    [Abstract] [Full Text] [Related]

  • 18. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia.
    Arango C, Gómez-Beneyto M, Brenlla J, Gastó C, Sarramea-Crespo F, Chamorro L, Masramon X, Díez T, ZIS Study Group.
    Eur Neuropsychopharmacol; 2007 May 01; 17(6-7):456-63. PubMed ID: 17234389
    [Abstract] [Full Text] [Related]

  • 19. Possible ziprasidone-induced mania.
    Larson MF, Hauser A.
    J Am Acad Child Adolesc Psychiatry; 2003 Sep 01; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
    [No Abstract] [Full Text] [Related]

  • 20. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
    Ku HL, Su TP, Chou YH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul 01; 30(5):963-4. PubMed ID: 16624468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.